Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Current Assets (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Current Assets for 8 consecutive years, with $738.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets fell 23.53% year-over-year to $738.8 million, compared with a TTM value of $738.8 million through Sep 2025, down 23.53%, and an annual FY2024 reading of $928.6 million, up 65.27% over the prior year.
  • Current Assets was $738.8 million for Q3 2025 at Bicycle Therapeutics, down from $804.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $1.0 billion in Q2 2024 and bottomed at $215.4 million in Q1 2021.
  • Average Current Assets over 5 years is $555.1 million, with a median of $458.6 million recorded in 2021.
  • The sharpest move saw Current Assets soared 194.47% in 2021, then dropped 23.53% in 2025.
  • Year by year, Current Assets stood at $458.6 million in 2021, then fell by 19.45% to $369.4 million in 2022, then skyrocketed by 52.11% to $561.9 million in 2023, then soared by 65.27% to $928.6 million in 2024, then fell by 20.44% to $738.8 million in 2025.
  • Business Quant data shows Current Assets for BCYC at $738.8 million in Q3 2025, $804.3 million in Q2 2025, and $856.1 million in Q1 2025.